Stay updated with breaking news from Global External. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Investegate announcements from INVENTIVA, Inventiva announces the screening of the first patient in LEGEND, a Phase IIa combination trial with lanifibranor and empagliflozin in patients with NASH and T2D
The Phase IIa Proof-of-Concept study is designed to assess the safety and efficacy of lanifibranor in combination with the SGLT2 inhibitor empagliflozin for the treatment of patients with non-cirrhotic
Inventiva successfully raised approximately €14.6 million through a combination of its ATM Program for €9.3 million and new State-backed bank financing for €5.3 millionIn accordance with the terms of the
Investegate announcements from INVENTIVA, Update on Inventiva's cash position and on the finance documentation with the European Investment Bank
Press release content from Business Wire. The AP news staff was not involved in its creation.